Renal sympathetic denervation in the aftermath of Symplicity HTN-3

References

• Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: A multicentre safety and proof-of-principle cohort study. Lancet. 2009;373: 1275–1281.
   PubMed Web of Science ®Google Scholar
• Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 Trial): A randomised controlled trial. Lancet. 2010;376: 1903–1909.
   PubMed Web of Science ®Google Scholar
• Krum H, Schlaich MP, Böhm M, Mahfoud F, Rocha-Singh K, Katholi R, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: Final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383:622–629.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, et al.; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393–1401.
   PubMed Web of Science ®Google Scholar
• Demaria AN. Reflections on renal denervation. J Am Coll Cardiol. 2014;63:1452–1453.
   PubMed Web of Science ®Google Scholar
• Von Euler US, Hellner S, Purkhold A. Excretion of noradrenaline in urine in hypertension. Scand J Clin Lab Invest. 1954; 6:54–59.
   PubMed Web of Science ®Google Scholar
• Julius S, Esler M. Autonomic nervous cardiovascular regulation in borderline hypertension. Am J Cardiol. 1975; 36:685–696.
   PubMed Web of Science ®Google Scholar
• Esler M, Zweifler A, Randall O, Julius S, DeQuattro V. Agreement among three different indices of sympathetic nervous system activity in essential hypertension. Mayo Clin Proc. 1977;52:379–382.
   PubMed Web of Science ®Google Scholar
• Eide I, Kolloch R, DeQuattro V, Miano L, Dugger R, Van der Meulen J. Raised cerebrospinal fluid norepinephrine in some patients with primary hypertension. Hypertension. 1979;1:255–260.
   PubMed Web of Science ®Google Scholar
• Esler M, Jackman G, Leonard P, Bobik A, Skews H, Jennings G, et al. Determination of noradrenaline uptake, spillover to plasma and plasma concentration in patients with essential hypertension. Clin Sci (Lond). 1980;59 Suppl 6:311s–313s.
   Web of Science ®Google Scholar
• Kjeldsen SE, Flaaten B, Eide I, Helgeland A, Leren P. Increased peripheral release of noradrenaline and uptake of adrenaline in essential hypertension? Clin Sci (Lond). 1981;61 Suppl 7:215s–217s.
   Web of Science ®Google Scholar
• Kjeldsen SE, Zweifler AJ, Petrin J, Weder AB, Julius S. Sympathetic nervous system involvement in essential hypertension: Increased platelet noradrenaline coincides with decreased beta-adrenoreceptor responsiveness. Blood Press. 1994;3:164–171.
   PubMedGoogle Scholar
• Gifford RW. An algorithm for the management of resistant hypertension. Hypertension. 1988;11:I-171–I-175.
   Web of Science ®Google Scholar
• Klein LE. Compliance and blood pressure control. Hypertension. 1988;11:I-161–I-164.
   Web of Science ®Google Scholar
• Ceral J, Habrdova V, Vorisek V, Bima M, Pelouch R, Solar M. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res. 2011;34:87–90.
   PubMed Web of Science ®Google Scholar
• Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350:757–764.
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al., for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359: 995–1003.
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M, Brunner H, Ekman S, Hansson L, et al. Cardiac events, stroke and mortality in high-risk hypertensives treated with valsartan or amlodipine: Main outcomes of The VALUE Trial. Lancet. 2004;363: 2022–2031.
   PubMed Web of Science ®Google Scholar
• Howard JP, Nowbar AN, Francis DP. Size of blood pressure reduction from renal denervation: Insights from meta-analysis of antihypertensive drug trials of 4,121 patients with focus on trial design: The CONVERGE report. Heart. 2013; 99:1579–1587.
   PubMed Web of Science ®Google Scholar
• Shun-Shin MJ, Howard JP, Francis DP. Removing the hype from hypertension. Symplicity HTN-3 illustrates the importance of randomisation and blinding for exciting new treatments. BMJ. 2014;348:g1937.
   Google Scholar
• O’Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, et al. European society of hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013; 31:1731–1768.
   PubMed Web of Science ®Google Scholar
• Persu A, O’Brien E, Verdecchia P. Use of ambulatory blood pressure measurement in the definition of resistant hypertension: A review of the evidence. Hypertens Res. 2014 Apr 17. doi: 10.1038/hr.2014.83. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Kikuya M, Hansen TW, Thijs L, Björklund-Bodegård K, Kuznetsova T, Ohkubo T, et al.; IDACO investigators. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Blood Press Monit. 2007;12:393–395.
   PubMed Web of Science ®Google Scholar
• Salles GF, Cardoso CR, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med. 2008;168:2340–2346.
   PubMed Web of Science ®Google Scholar
• Azizi M, Steichen O, Frank M, Bobrie G, Plouin PF, Sapoval M. Catheter-based radiofrequency renal-nerve ablation in patients with resistant hypertension. Eur J Vasc Endovasc Surg. 2012;43:293–299.
   PubMed Web of Science ®Google Scholar
• Persu A, Renkin J, Thijs L, Staessen JA. Renal denervation: Ultima ratio or standard in treatment-resistant hypertension. Hypertension. 2012;60:596–606.
   PubMed Web of Science ®Google Scholar
• Staessen JA, Thijs L, Bieniaszewski L, O’Brien ET, Palatini P, Davidson C, et al. Ambulatory monitoring uncorrected for placebo overestimates long-term antihypertensive action. Systolic Hypertension in Europe (SYST-EUR) Trial Investigators. Hypertension. 1996;27:414–420.
   PubMed Web of Science ®Google Scholar
• Lüscher TF, Mahfoud F. Renal nerve ablation after Symplicity HTN-3: Confused at the higher level? Eur Heart J. 2014; 35:1706–1711.
   PubMed Web of Science ®Google Scholar
• Persu A, Azizi M, Burnier M, Staessen JA. Residual effect of renal denervation in patients with truly resistant hypertension. Hypertension. 2013;62:450–452.
   PubMed Web of Science ®Google Scholar
• Fadl Elmula FEM, Hoffmann P, Fossum E, Brekke M, Gjønnæss E, Hjørnholm U, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension. 2013;62:526–532.
   PubMed Web of Science ®Google Scholar
• Persu A, Renkin J, Asayama K, O’Brien E, Staessen JA. Renal denervation in treatment-resistant hypertension: The need for restraint and more and better evidence. Expert Rev Cardiovasc Ther. 2013;11:739–749.
   PubMedGoogle Scholar
• Persu A, Jin Y, Azizi M, Baelen M, Völz S, Elvan A, et al., on behalf of the European Network Coordinating research on REnal denervation (ENCOReD). Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens. 2014;28:150–156.
   PubMed Web of Science ®Google Scholar
• Helgeland A. Treatment of mild hypertension: A five year controlled drug trial. The Oslo study. Am J Medicine. 1980: 69:725–732.
   Google Scholar
• Brinkmann J, Heusser K, Schmidt BM, Menne J, Klein G, Bauersachs J, et al. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: Prospective case series. Hypertension. 2012;60:1485–1490.
   PubMed Web of Science ®Google Scholar
• Fadl Elmula FEM, Hoffman P, Larstorp AC, Fossum E, Brekke M, Kjeldsen SE, et al. Adjusted drug treatment is superior to sympathetic renal denervation in patients with true treatment resistant hypertension. Hypertension. 2014;63:691–699.
   Web of Science ®Google Scholar
• Mahfoud F, Ukena C, Schmieder RE, Cremers B, Rump LC, Vonend O, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation. 2013;128:132–140.
   PubMed Web of Science ®Google Scholar
• Ott C, Mahfoud F, Schmid A, Ditting T, Sobotka PA, Veelken R, et al. Renal denervation in moderate treatment-resistant hypertension. J Am Coll Cardiol. 2013;62:1880–1886.
   PubMed Web of Science ®Google Scholar
• Jin Y, Persu A,Staessen JA. Letter by Jin et al. regarding article, “Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension”. Circulation. 2014;129:e499.
   Web of Science ®Google Scholar
• Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K, et al. ESH position paper: Renal denervation – An interventional therapy of resistant hypertension. J Hypertens. 2012;30:837–841.
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K, et al. Updated ESH position paper on interventional therapy of resistant hypertension. Euro Intervention. 2013;9:R58–R66.
   Google Scholar
• Schmieder RE. How should data from Symplicity HTN3 be interpreted? Nat Rev Cardiol. Advance online publication 20 May 2014; doi:10.1038/nrcardio.2014.70.
   Google Scholar
• Pathak A, Ewen S, Fajadet J, Honton B, Mahfoud F, Marco J, et al. From Symplicity HTN-3 to the Renal Denervation Global Registry: Where do we stand and where should we go? Euro Intervention. 2014;10:21–23.
   Google Scholar
• Longland CJ, Gibb WE. Sympathectomy in the treatment of benign and malignant hypertension; A review of 76 patients. Br J Surg. 1954;41:382–392.
   PubMed Web of Science ®Google Scholar
• Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension, results in 1,266 cases. JAMA. 1953; 152:1501–1504.
   PubMed Web of Science ®Google Scholar
• Persu A, Jin Y, Baelen M, Vink E, Verloop WL, Schmidt B, et al.;European Network Coordinating research on REnal Denervation (ENCOReD) Consortium. Eligibility for renal denervation: Experience at 11 European expert centers. Hypertension. 2014;63:1319–1325.
   PubMed Web of Science ®Google Scholar
• Persu A Jin Y, Fadl Elmula FEM, Jacobs L, Renkin J, Kjeldsen SE. Renal denervation after Symplicity HTN-3: An update. Curr Hypertens Rep. 2014;16:460. DOI 10.1007/s11906-014-0460-x.
   PubMed Web of Science ®Google Scholar
• Oz M. Pressure relief. This year brings a breakthrough procedure to fight hypertension. Time Magazine. 2012, January 9, page 28.
   Google Scholar
• Blech J. Vergebens verbrutzelt. Ein Eingriff an den Nierennerven gilt als neues Wundermittel gegen Bluthochdruck. Dabei ist nicht bewiesen, dass die Methode den Patienten wirklich nutzt. Der Spiegel. 2013, No. 28:102–103.
   Google Scholar
• Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm. 2006;12:239–245.
   PubMed Web of Science ®Google Scholar